Nifty
Sensex
:
:
17149.10
57491.51
-468.05 (-2.66%)
-1545.67 (-2.62%)

Pharmaceuticals & Drugs - Global

Rating :
58/99

BSE: 500420 | NSE: TORNTPHARM

3165.15
21-Jan-2022
  • Open
  • High
  • Low
  • Previous Close
  •  3190.30
  •  3219.75
  •  3141.15
  •  3204.80
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  95976
  •  3057.70
  •  3298.50
  •  2311.10

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 53,478.42
  • 42.06
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 57,749.05
  • 1.11%
  • 8.57

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 71.25%
  • 0.45%
  • 7.30%
  • FII
  • DII
  • Others
  • 11.63%
  • 8.87%
  • 0.50%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.50
  • 6.60
  • 1.42

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.29
  • 12.36
  • 4.53

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.99
  • 6.04
  • 42.10

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 31.96
  • 39.14
  • 41.10

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 6.68
  • 6.59
  • 7.41

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.80
  • 18.06
  • 19.32

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 21
Sep 20
Var%
Jun 21
Jun 20
Var%
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Net Sales
2,137.00
2,017.00
5.95%
2,134.00
2,056.00
3.79%
1,937.00
1,946.00
-0.46%
1,995.00
1,966.00
1.48%
Expenses
1,477.00
1,382.00
6.87%
1,457.00
1,395.00
4.44%
1,355.00
1,398.00
-3.08%
1,388.00
1,426.00
-2.66%
EBITDA
660.00
635.00
3.94%
677.00
661.00
2.42%
582.00
548.00
6.20%
607.00
540.00
12.41%
EBIDTM
30.88%
31.48%
31.72%
32.15%
30.05%
28.16%
30.43%
27.47%
Other Income
51.00
6.00
750.00%
40.00
4.00
900.00%
39.00
15.00
160.00%
8.00
53.00
-84.91%
Interest
71.00
92.00
-22.83%
68.00
102.00
-33.33%
73.00
102.00
-28.43%
91.00
111.00
-18.02%
Depreciation
168.00
165.00
1.82%
165.00
161.00
2.48%
165.00
168.00
-1.79%
167.00
163.00
2.45%
PBT
472.00
384.00
22.92%
484.00
402.00
20.40%
383.00
293.00
30.72%
357.00
319.00
11.91%
Tax
156.00
74.00
110.81%
154.00
81.00
90.12%
59.00
-21.00
-
60.00
68.00
-11.76%
PAT
316.00
310.00
1.94%
330.00
321.00
2.80%
324.00
314.00
3.18%
297.00
251.00
18.33%
PATM
14.79%
15.37%
15.46%
15.61%
16.73%
16.14%
14.89%
12.77%
EPS
18.67
18.32
1.91%
19.50
18.97
2.79%
19.14
18.55
3.18%
17.55
14.83
18.34%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Net Sales
8,203.00
8,004.83
7,939.31
7,672.80
5,949.83
5,815.69
6,666.85
4,653.45
4,184.72
3,211.14
2,695.92
Net Sales Growth
2.73%
0.83%
3.47%
28.96%
2.31%
-12.77%
43.27%
11.20%
30.32%
19.11%
 
Cost Of Goods Sold
2,241.00
1,960.12
1,981.79
2,041.26
1,535.17
1,629.66
1,432.13
1,280.96
1,107.58
807.98
774.38
Gross Profit
5,962.00
6,044.71
5,957.52
5,631.54
4,414.66
4,186.03
5,234.72
3,372.49
3,077.14
2,403.16
1,921.54
GP Margin
72.68%
75.51%
75.04%
73.40%
74.20%
71.98%
78.52%
72.47%
73.53%
74.84%
71.28%
Total Expenditure
5,677.00
5,538.23
5,768.95
5,696.31
4,600.58
4,438.42
3,937.05
3,633.29
3,233.24
2,518.92
2,195.46
Power & Fuel Cost
-
122.94
128.19
132.46
118.77
107.98
92.59
97.41
71.88
62.80
56.97
% Of Sales
-
1.54%
1.61%
1.73%
2.00%
1.86%
1.39%
2.09%
1.72%
1.96%
2.11%
Employee Cost
-
1,439.62
1,429.04
1,403.79
1,135.25
993.41
842.35
841.81
741.10
623.29
531.80
% Of Sales
-
17.98%
18.00%
18.30%
19.08%
17.08%
12.63%
18.09%
17.71%
19.41%
19.73%
Manufacturing Exp.
-
550.92
544.11
558.84
457.58
502.16
353.45
345.98
320.78
278.15
225.27
% Of Sales
-
6.88%
6.85%
7.28%
7.69%
8.63%
5.30%
7.43%
7.67%
8.66%
8.36%
General & Admin Exp.
-
647.22
801.98
763.90
677.71
578.05
637.92
463.28
398.98
324.55
255.89
% Of Sales
-
8.09%
10.10%
9.96%
11.39%
9.94%
9.57%
9.96%
9.53%
10.11%
9.49%
Selling & Distn. Exp.
-
742.63
807.39
738.03
641.30
567.70
547.05
574.40
461.53
393.07
322.29
% Of Sales
-
9.28%
10.17%
9.62%
10.78%
9.76%
8.21%
12.34%
11.03%
12.24%
11.95%
Miscellaneous Exp.
-
74.78
76.45
58.03
34.80
59.46
31.56
29.45
131.39
29.08
322.29
% Of Sales
-
0.93%
0.96%
0.76%
0.58%
1.02%
0.47%
0.63%
3.14%
0.91%
1.07%
EBITDA
2,526.00
2,466.60
2,170.36
1,976.49
1,349.25
1,377.27
2,729.80
1,020.16
951.48
692.22
500.46
EBITDA Margin
30.79%
30.81%
27.34%
25.76%
22.68%
23.68%
40.95%
21.92%
22.74%
21.56%
18.56%
Other Income
138.00
75.73
121.30
63.62
298.84
223.30
228.80
285.55
38.13
43.36
44.70
Interest
303.00
358.28
450.71
503.75
308.48
205.56
183.98
175.16
58.63
33.80
39.45
Depreciation
665.00
657.79
654.38
617.69
408.60
306.92
237.55
190.74
87.00
82.69
81.73
PBT
1,696.00
1,526.26
1,186.57
918.67
931.01
1,088.09
2,537.07
939.81
843.98
619.09
423.98
Tax
429.00
274.38
161.85
125.35
252.87
154.51
610.17
188.84
180.07
146.69
72.32
Tax Rate
25.29%
17.98%
13.64%
22.32%
27.16%
14.20%
26.04%
20.09%
21.34%
25.22%
20.17%
PAT
1,267.00
1,251.88
1,024.72
436.28
678.11
933.55
1,733.24
750.94
663.88
432.76
284.04
PAT before Minority Interest
1,267.00
1,251.88
1,024.72
436.31
678.14
933.58
1,733.27
750.97
663.91
434.91
286.30
Minority Interest
0.00
0.00
0.00
-0.03
-0.03
-0.03
-0.03
-0.03
-0.03
-2.15
-2.26
PAT Margin
15.45%
15.64%
12.91%
5.69%
11.40%
16.05%
26.00%
16.14%
15.86%
13.48%
10.54%
PAT Growth
5.94%
22.17%
134.88%
-35.66%
-27.36%
-46.14%
130.81%
13.11%
53.41%
52.36%
 
EPS
74.88
73.99
60.56
25.78
40.08
55.17
102.44
44.38
39.24
25.58
16.79

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Shareholder's Funds
5,837.17
4,823.22
4,724.35
4,622.19
4,350.13
3,494.10
2,490.56
1,902.43
1,421.93
1,193.83
Share Capital
84.62
84.62
84.62
84.62
84.62
84.62
84.62
84.62
42.31
42.31
Total Reserves
5,752.55
4,738.60
4,639.73
4,537.57
4,265.51
3,409.48
2,405.94
1,817.81
1,379.62
1,151.52
Non-Current Liabilities
2,924.20
3,299.15
3,861.40
4,142.42
2,303.33
1,994.65
2,504.92
926.76
619.81
487.73
Secured Loans
2,963.27
3,302.29
3,909.81
4,105.31
2,229.57
1,839.46
2,171.60
730.72
403.19
223.83
Unsecured Loans
0.00
1.56
3.11
6.15
11.26
10.62
13.62
13.74
51.35
98.22
Long Term Provisions
369.62
338.34
288.52
286.66
263.04
246.36
207.49
190.43
129.51
110.45
Current Liabilities
4,891.62
5,454.16
5,165.32
5,202.17
2,738.26
3,285.48
2,823.75
2,174.58
1,710.65
1,362.84
Trade Payables
2,066.81
2,048.81
2,096.74
2,048.24
1,749.32
2,260.22
1,827.72
1,429.13
1,067.74
863.47
Other Current Liabilities
1,635.36
1,860.80
1,641.26
1,151.68
687.14
822.28
446.15
371.63
275.83
291.00
Short Term Borrowings
704.40
1,090.85
934.11
1,625.60
0.00
3.32
319.07
210.43
124.62
138.12
Short Term Provisions
485.05
453.70
493.21
376.65
301.80
199.66
230.81
163.39
242.46
70.25
Total Liabilities
13,652.99
13,576.53
13,751.07
13,967.30
9,392.21
8,774.69
7,819.66
5,004.17
3,752.76
3,047.90
Net Block
7,064.63
7,533.12
7,747.71
7,854.68
3,688.44
2,859.08
2,832.66
875.34
819.82
796.87
Gross Block
10,511.53
10,334.13
9,935.43
9,449.48
4,909.80
3,793.53
3,542.93
1,420.04
1,278.15
1,199.64
Accumulated Depreciation
3,446.90
2,801.01
2,187.72
1,594.80
1,221.36
934.45
710.27
544.70
458.33
402.77
Non Current Assets
8,129.77
8,595.61
8,713.53
8,704.89
4,512.74
4,085.66
3,768.25
1,599.69
1,191.87
1,060.78
Capital Work in Progress
889.38
711.93
617.12
646.94
519.49
1,041.58
678.33
534.11
285.28
113.55
Non Current Investment
42.09
2.09
2.09
0.09
0.09
0.09
0.06
0.03
0.03
37.52
Long Term Loans & Adv.
81.56
222.19
150.58
130.96
182.32
99.66
206.92
129.47
62.84
61.37
Other Non Current Assets
52.11
126.28
196.03
72.22
122.40
85.25
50.28
60.74
23.90
46.25
Current Assets
5,523.22
4,980.92
5,037.54
5,262.41
4,879.47
4,689.03
4,051.41
3,404.48
2,560.89
1,987.12
Current Investments
139.05
0.02
351.35
492.27
803.55
779.59
297.59
185.63
60.44
86.52
Inventories
2,681.20
2,148.22
1,935.15
1,966.30
1,559.15
1,357.98
1,067.17
1,006.06
923.86
531.56
Sundry Debtors
1,523.37
1,649.34
1,435.71
1,253.45
950.89
1,445.09
1,587.26
1,099.42
687.82
522.80
Cash & Bank
603.50
666.65
816.04
867.23
893.72
647.03
567.36
769.42
626.97
674.28
Other Current Assets
576.10
443.21
405.83
587.77
672.16
459.34
532.03
343.95
261.80
171.96
Short Term Loans & Adv.
62.32
73.48
93.46
95.39
82.62
90.18
109.09
84.95
75.95
56.46
Net Current Assets
631.60
-473.24
-127.78
60.24
2,141.21
1,403.55
1,227.66
1,229.90
850.24
624.28
Total Assets
13,652.99
13,576.53
13,751.07
13,967.30
9,392.21
8,774.69
7,819.66
5,004.17
3,752.76
3,047.90

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Cash From Operating Activity
2,010.69
1,392.91
1,798.08
894.15
1,008.84
2,742.12
810.20
599.42
153.48
499.13
PBT
1,526.26
1,186.57
561.66
931.01
1,088.09
2,343.44
939.81
843.98
581.60
358.62
Adjustment
998.18
876.21
1,418.19
606.92
430.27
552.44
337.96
136.79
126.13
79.64
Changes in Working Capital
-338.25
-385.83
99.39
-360.16
-125.21
423.58
-409.38
-119.68
-421.75
143.58
Cash after chg. in Working capital
2,186.19
1,676.95
2,079.24
1,177.77
1,393.15
3,319.46
868.39
861.09
285.98
581.84
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-175.50
-284.04
-281.16
-283.62
-384.31
-577.34
-58.19
-261.67
-132.50
-82.71
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-449.42
198.61
-241.28
-4,706.95
-786.91
-837.85
-2,162.30
-355.81
-241.70
-136.97
Net Fixed Assets
-198.83
-378.80
-610.74
-4,245.22
-592.01
-471.42
-2,266.57
-308.01
-455.28
-84.67
Net Investments
-179.03
351.33
138.83
310.79
-17.69
-484.32
-111.97
-131.60
287.55
-47.29
Others
-71.56
226.08
230.63
-772.52
-177.21
117.89
216.24
83.80
-73.97
-5.01
Cash from Financing Activity
-1,656.13
-1,549.04
-1,314.45
3,417.39
-192.91
-1,435.15
1,212.25
86.40
19.73
-192.74
Net Cash Inflow / Outflow
-94.86
42.48
242.35
-395.41
29.02
469.12
-139.85
330.01
-68.49
169.42
Opening Cash & Equivalents
661.82
588.76
702.04
1,067.57
1,049.86
612.38
955.05
687.41
760.80
604.79
Closing Cash & Equivalent
572.56
661.82
940.06
702.04
1,067.57
1,049.86
864.95
955.05
687.41
760.80

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Book Value (Rs.)
344.90
284.99
279.15
273.11
257.04
206.46
147.16
112.41
84.02
70.54
ROA
9.20%
7.50%
3.15%
5.81%
10.28%
20.89%
11.71%
15.16%
12.79%
10.26%
ROE
23.49%
21.47%
9.34%
15.12%
23.80%
57.92%
34.19%
39.94%
33.25%
25.84%
ROCE
17.63%
15.28%
9.75%
13.81%
20.36%
45.63%
26.98%
35.06%
31.66%
23.65%
Fixed Asset Turnover
1.43
1.48
1.50
1.57
1.35
1.82
1.88
3.11
2.60
2.50
Receivable days
38.92
37.65
33.78
35.74
74.66
82.76
105.19
77.81
68.65
58.33
Inventory Days
59.24
49.84
49.01
57.16
90.90
66.19
81.17
84.02
82.53
70.03
Payable days
129.90
133.47
139.05
150.99
171.27
204.35
176.11
158.58
143.69
136.22
Cash Conversion Cycle
-31.74
-45.98
-56.26
-58.09
-5.72
-55.41
10.25
3.25
7.50
-7.86
Total Debt/Equity
0.84
1.21
1.28
1.40
0.58
0.67
1.10
0.59
0.49
0.48
Interest Cover
5.26
3.63
2.11
4.02
6.29
13.74
6.37
15.40
18.21
10.09

News Update:


  • Torrent Pharmaceuticals to launch Molnupiravir under brand name Molnutor in India
    28th Dec 2021, 15:58 PM

    Molnupiravir is the oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency

    Read More
  • Torrent Pharma recalling over 27,000 bottles of blood pressure lowering drug in US
    27th Dec 2021, 17:44 PM

    The affected lot has been produced in India and later the company has supplied to its US-based subsidiary for distribution in the US

    Read More
  • USFDA inspects Torrent Pharmaceuticals’ USA manufacturing facility
    16th Dec 2021, 17:13 PM

    At the end of the inspection No Form 483 was issued

    Read More
  • Torrent Pharmaceuticals redeems NCDs worth Rs 150 crore
    14th Dec 2021, 12:18 PM

    The company has redeemed and repaid NCDs on December 13, 2021

    Read More
  • Torrent Pharma - Quarterly Results
    26th Oct 2021, 17:48 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.